Prestige Consumer Healthcare (PBH) Beats Q2 2027 Estimates but Cuts Full-Year Guidance
As seen on the 24/7 Wall St. homepage on November 5, 2026.
Management cut full-year adjusted EPS guidance to $4.48 to $4.55 from $4.55 to $4.65, blaming Clear Eyes production problems at the newly acquired Pillar5 plant that will limit supply all second half. The double beat came entirely from acquisitions, with organic revenue down 1.6%.
Continue ReadingShow less
Prestige Consumer Healthcare reported adjusted EPS of $1.13 for its fiscal second quarter of 2027, meeting expectations on revenue of $336.3 million and clearing consensus on earnings. The composition of those results is more complicated than the double beat suggests.
The entire revenue outperformance was acquisition-driven. The Breathe Right portfolio and LaCorium deals, which closed in June and July respectively, together contributed $65.1 million in revenue during the quarter. Strip those out and organic revenue actually declined 1.6%, weighed down by order-timing shifts that pulled demand into the first quarter and a drop in Clear Eyes sales.
Clear Eyes is now the central concern for the second half. Management pointed to production variability at the newly acquired Pillar5 plant as the culprit, saying limited supply will constrain product availability through the remainder of the fiscal year. As a result, Prestige trimmed its full-year adjusted EPS guidance to $4.48 to $4.55 from a prior range of $4.55 to $4.65, and cut its revenue target to $1.28 billion to $1.29 billion.
Sponsored
CEO Ron Lombardi framed the guidance cut narrowly, saying the outlook for the rest of the portfolio is unchanged and that the company continues to invest in the Pillar5 facility with the goal of building consistent long-term output for the Clear Eyes brand. He also reiterated the company's medium-term targets of roughly 10% annual revenue growth and roughly 8% annual EPS growth.
Prestige missed estimates in Q1 2026, Q2 2026, Q3 2026, and Q4 2026 before returning to beats in Q1 2027 and now Q2 2027. The back-to-back beats are encouraging, but investors will be watching whether the Pillar5 disruption deepens or resolves as the company moves through the second half of fiscal 2027.
Mentioned: PBH